ArticleBiomedical engineering and computational biology2026
Computational Screening of Microbial Metabolites as Erythropoietin (EPO) Mimetics for the Treatment of Anemia.
Article in Biomedical engineering and computational biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anemia remains a critical global health burden, often driven by impaired erythropoietin (EPO) signaling, which reduces red blood cell production. While recombinant EPO therapy is effective, its high cost and associated safety concerns limit its accessibility. This study explores microbial metabolites as affordable and safe alternatives that act as EPO mimetics that can bind and activate the erythropoietin receptor (EPOR). A computational screening of 90 microbial bioactive compounds was conducted, and from those, 16 were selected for detailed analysis. The extracellular domain of EPOR (PDB: 1EBP) was used as the target protein. Molecular docking was performed using AutoDock, followed by ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) profiling with SwissADME and ProTox-III. Protein-protein interaction (PPI) networks were also analyzed in Cytoscape, and the stability of the top complexes was validated via 100 ns molecular dynamics (MD) simulations. Docking results identified Abyssomicin W, Abyssomicin C, and Camptothecin as the top candidates with strong binding affinities (-7.60 kcal/mol) to EPOR. ADMET predictions confirmed their favorable drug-likeness and safety profiles, with Abyssomicin W exhibiting the most promising characteristics, including high gastrointestinal absorption, and no predicted hepatotoxicity or carcinogenicity. PPI network analysis underscored the functional relevance of EPOR in erythropoietic pathways, while molecular dynamics (MD) simulations revealed that Abyssomicin W and Camptothecin formed highly stable complexes with the receptor, whereas the Abyssomicin C complex was unstable. The integrated computational pipeline successfully identified Abyssomicin W as the most stable and promising EPO mimetic candidate. In conclusion, this study identifies Abyssomicin W as a potential and stable EPO mimetic candidate, highlighting the potential of microbial metabolites as cost-effective therapeutics for anemia. Further experimental validation, including direct binding and functional cell-based assays is recommended to confirm its efficacy and safety in biological systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.